Antithymocyte globulin, pretransplant blood transfusion, and tissue typing in cadaver kidney transplantation

Area of Science:

• Nephrology
• Immunology
• Transplantation

Background:

• Kidney transplantation is a vital treatment for end-stage renal disease.
• Optimizing transplant outcomes requires understanding factors influencing graft survival.
• Immunosuppression and donor-recipient matching are critical considerations.

Purpose of the Study:

• To evaluate the impact of antithymocyte globulin (ATG) therapy on primary cadaver kidney transplant survival.
• To assess the influence of pretransplant blood transfusions, HLA antigen matching, and panel reactive antibodies (PRA) on transplant outcomes.
• To identify key predictors of successful kidney allograft survival.

Main Methods:

• Analysis of 347 primary cadaver kidney transplant recipients.
• Comparison of outcomes between patients receiving prophylactic ATG and those not treated with ATG.
• Evaluation of the effects of pretransplant blood transfusions, HLA-A, -B, and -DR antigen mismatches, and PRA levels.

Main Results:

• Prophylactic ATG therapy significantly increased kidney transplant survival compared to the non-ATG group.
• The beneficial effect of pretransplant blood transfusions was diminished in recipients receiving prophylactic ATG.
• No significant correlation was found between HLA-A and -B antigen matches and transplant survival.
• Transplant survival showed no significant difference between zero and one DR antigen match, with limited data for two DR matches.
• Recipients who did not develop PRA after transfusions had better transplant survival.

Conclusions:

• Prophylactic ATG therapy is a significant factor in improving kidney transplant survival.
• The role of pretransplant blood transfusions in enhancing survival is reduced when ATG is administered prophylactically.
• HLA-A, -B, and -DR matching, particularly at the DR locus, show limited impact on early transplant survival in this cohort, suggesting other factors may be more dominant.